Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis.
Tian T, Li Y, Li J, Xu H, Fan H, Zhu J, Wang Y, Peng F, Gong Y, Du Y, Yan X, He X, Cali Daylan AE, Pircher A, Neibart SS, Okuma Y, Hong MH, Huang M, Lu Y. Tian T, et al. Among authors: okuma y. Transl Lung Cancer Res. 2024 Apr 29;13(4):861-874. doi: 10.21037/tlcr-24-116. Epub 2024 Apr 24. Transl Lung Cancer Res. 2024. PMID: 38736501 Free PMC article.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, Goto H, Yoneda H, Harada T, Kubota Y, Yamada T, Date K, Shiotsu S, Nagata K, Chihara Y, Kaneko Y, Uchino J, Nishioka Y, Takayama K. Yoshimura A, et al. Among authors: okuma y. Transl Lung Cancer Res. 2019 Aug;8(4):450-460. doi: 10.21037/tlcr.2019.08.07. Transl Lung Cancer Res. 2019. PMID: 31555518 Free PMC article.
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study.
Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, Shiotsu S, Kunimasa K, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Kenmotsu H, Takahashi T, Takayama K. Yoshimura A, et al. Among authors: okuma y. Transl Lung Cancer Res. 2021 Aug;10(8):3582-3593. doi: 10.21037/tlcr-21-461. Transl Lung Cancer Res. 2021. PMID: 34584858 Free PMC article.
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
Torasawa M, Yoshida T, Yagishita S, Shimoda Y, Shirasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y. Torasawa M, et al. Among authors: okuma y. Lung Cancer. 2022 May;167:49-57. doi: 10.1016/j.lungcan.2022.03.020. Epub 2022 Apr 4. Lung Cancer. 2022. PMID: 35397298
560 results